
|Videos|May 17, 2019
Investigating Toxicities With Lenvatinib Plus Paclitaxel in Ovarian and Endometrial Cancers
Author(s)Floor J. Backes, MD
Floor J. Backes, MD, discusses the side effects associated with the combination lenvatinib plus paclitaxel in patients with recurrent endometrial and platinum-resistant epithelial ovarian cancer.
Advertisement
Floor J. Backes, MD, associate professor at The Ohio State University Comprehensive Cancer Center, discusses the side effects associated with
The toxicities were typical to that of other chemotherapy agents, says Backes. This includes cytopenia, anemia, leukopenia, and some thrombocytopenia. It was mostly the white and red cells that were affected.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5



































